Day Two

Explore the Agenda

Pre-Conference Day

Monday, July 21

Day One

Tuesday, July 22

Day Two

Wednesday, July 23

7:00 am Check In & Morning Coffee

7:45 am Chair’s Opening Remarks

Jason Zhang

Co-Founder & Chief Executive Officer, Zipcode Bio

Envisioning the Success of mRNA Therapeutics & Vaccines Enabled by Robust Biopharma Partnerships, Licensing & Capital Investment

7:55 am Biopharma Business Development & Investors Panel: Secure the Financial Future of mRNA Technology Through Trusting Investor Partnerships

Ashoka Madduri

Global Head of Scientific Strategy & Intelligence, mRNA Center of Excellence, Sanofi

Richard Shen

Managing Director & Interim Chief Executive Officer, Sedgwick Yard & Endotope Biosciences

Ilya Vensky

General Partner, Provisio Ventures

David Kolesky

Principal, MPM BioImpact

Kristin Thompson

Director - Investment, Merieux Equity Partners

Tej Pavoor

Partner, Delos Capital

Thaminda Ramanayake

Chief Business Officer, CureVac SE

Download the Full Event Guide to see session details.

8:35 am Session Reserved for ReciBiopharm

9:05 am A Look into the RNA Deals & Companies Landscape

Ioana Panait

Senior Researcher, Beacon

Download the Full Event Guide to see session details.

9:15 am Advanced Patenting Considerations for mRNA Market Players & New Entrants

Dan Shores

Partner, Rothwell Figg

Download the Full Event Guide to see session details.

9:45 am Session Reserved for Cytiva

10:15 am Morning Break & Networking

Discovery Pre-Clinical Development Clinical Manufacturing & CMC

Discovery

Unravelling Novel Approaches for mRNA-LNP Delivery From Genetic Circuits to Gene Editing in Pre-Clinical Models – Chair

Rachel Groppo

Director, Lead Self-Amplifying RNA Team, Johnson & Johnson

10:45 am RNA-based Genome Engineering by Target-Primed Reverse Transcription

Chauncey Zeng

Associate Director, Tessera Therapeutics

Download the Full Event Guide to see session details.

11:15 am Platinum® Pro Protein Barcoding: Advancing mRNA Drug Development through Multiplexed mRNA Screening with Direct Protein-Level Detection

Joel McDade PhD

Director of Technical Sales, Quantum Si

Download the Full Event Guide to see session details.

11:45 am Preclinical Evaluation of Targeted LNPs (tLNPs) for In Vivo HSC Delivery & Editing

Jimit Raghav

Scientist II, DMPK, Editas Medicine

Download the Full Event Guide to see session details.

Pre-Clinical Development

Harnessing Suitable Model Systems for the Testing & Development of Influenza Vaccines with Longevity & Efficacy at Low Doses – Chair

John Zuris

Senior Director - Delivery and Editing Technologies, Editas Medicine

10:45 am Self-Amplifying mRNA Influenza Vaccines: Achieving Longevity & Efficacy at Low Doses

Lingtao Peng

Director, CSL

Download the Full Event Guide to see session details.

11:15 am Development of Ligand-Targeted Multivalent mRNA Influenza Vaccines

Daryl Drummond

Chief Scientific Officer, Akagera Medicines

Download the Full Event Guide to see session details.

11:45 am Please Join Sessions in Either Discovery or Manufacturing & CMC Tracks

Clinical

Determining Clinical End-Points to Achieve Key Milestones in the Development of mRNA Vaccines & Therapies

10:45 am Harnessing mRNA/LNP Technology: Clinical & Preclinical Milestones in Vaccine Development & Therapeutics Research

Zach Zhu

Chief Technology Officer, Innorna

Download the Full Event Guide to see session details.

11:15 am Optimized Self-Replicating RNA Enable Low Dose & Single Dose Vaccine Applications in the Clinic

Nathaniel Wang

Chief Executive Officer & Co-Founder, Replicate Bioscience

Download the Full Event Guide to see session details.

11:45 am Please Join Sessions in Either Discovery or Manufacturing & CMC Tracks

Manufacturing & CMC

Achieving Effective Sourcing & Process Development to Achieve Cheaper & High-Quality mRNA for All Applications – Chair

Kinkini Roy

Associate Director, Drug Product Development, Aviceda Therapeutics

10:45 am Novel Development & Manufacturing Strategies for Reducing mRNA-LNP Cost of Goods

Joe Parrella

cmc, Kernal Bio

Download the Full Event Guide to see session details.

11:15 am Implementation of Phase Appropriate mRNA Analytics in a Contract Testing Environment: Balancing the Development & Qualification Approach in a mRNA Program

Jeff Heiser

Chief Scientific Officer, Microbial & Advanced Therapeutic Platforms, BA Sciences

Download the Full Event Guide to see session details.

11:45 am Journey Into the Development of mRNA-based Epigenic Editor

SHEFAL PARIKH

SR DIRECTOR PROCESS DEV, nChromaBio

Download the Full Event Guide to see session details.

12:15 pm Lunch & Networking Break

Discovery Pre-Clinical Development Clinical Manufacturing & CMC

Discovery

Unravelling Novel Approaches for Self-Amplifying RNA Technology Discoveries to Successfully Target the Tumour – Chair

Rachel Groppo

Director, Lead Self-Amplifying RNA Team, Johnson & Johnson

1:15 pm STX-003: Targeting IL-12 Expression to Tumors via mRNA Programmed With Genetic Circuits

Allen Tseng

Senior Principal Scientist, Strand Therapeutics

Download the Full Event Guide to see session details.

1:45 pm dsRNA Control in mRNA Manufacturing：From Reduction to Detection

Jingchao Xi, PhD

Project Manager, Vazyme

Download the Full Event Guide to see session details.

Pre-Clinical Development

Supercharging mRNA Immunotherapies with Improved Expression & Immunogenicity Towards Translatable & Clinically Ready Drugs

John Zuris

Senior Director - Delivery and Editing Technologies, Editas Medicine

1:15 pm Encoding Active Antigen-Specific Immune Tolerance Using mRNA-LNPs for the Treatment of Autoimmune Diseases

Jessica Kenison-White

Scientific Director, Immunocodex

Download the Full Event Guide to see session details.

1:45 pm Efficacy & Safety of a New Active mRNA Immunotherapy for Allergic Asthma

Vincent Serra

Chief Scientific & Operating Officer, Arnity Therapeutics

Download the Full Event Guide to see session details.

Clinical

Leveraging Insights on the Current mRNA Therapeutic Landscape & Potential Clinical Applications for New Targets

1:15 pm Advances in Therapeutics Genome Editing with Cas9 mRNA

Weijun Chen

Director, Rna Technologies Lead, Intellia Therapeutics

Download the Full Event Guide to see session details.

1:45 pm A Review of the mRNA-Based Drug Development Landscape

Ioana Panait

Senior Researcher, Beacon

Download the Full Event Guide to see session details.

Manufacturing & CMC

Preparing for Effective CMC Strategy Through Assay Development & Regulatory Requirements – Chair

Kinkini Roy

Associate Director, Drug Product Development, Aviceda Therapeutics

1:15 pm Round Table Discussion: Reimagining Potency & Release Specifications to Tailor Analytical Development Towards Better Characterized mRNA Drug Substance & Products

Diana M Posadas

Director - Strategic Research, GreenLight BioSciences

Jianmei Kochling

Site Head & Senior Director - Analytical Development CMC, mRNA Excellence, Vaccine R&D, Sanofi

Download the Full Event Guide to see session details.

1:45 pm Guide To Lean Manufacturing: Redefining The Concept of mRNA Development

Scott Alderucci

Director, Process Development, Curia

Download the Full Event Guide to see session details.

2:15 pm Afternoon Break & Networking

The Next Wave: Turbocharging Circular RNA Technology Development Towards Effective Vaccine & Therapeutic Applications

2:45 pm Circular RNA: Transforming a Promising Technology Into Cutting-Edge Therapeutics

Edo Kon

Director - Business Development, RiboX Therapeutics

Download the Full Event Guide to see session details.

3:15 pm Scarless Circular mRNA-Based CAR-T Cell Therapy Exhibits Potent Pharmacological Activity

Xian Zeng

Co-Founder & CEO, Byterna Therapeutics

Download the Full Event Guide to see session details.

3:45 pm CircRNA Platform & the Development of Therapeutics

Chijan Zuo

Vice president, CureMed Biomedical Technology

Download the Full Event Guide to see session details.

4:15 pm Chair’s Closing Remarks

Jason Zhang

Co-Founder & Chief Executive Officer, Zipcode Bio

4:30 pm End of 5th mRNA-Based Therapeutics Summit 2025

View Event Brochure

Pre-Conference Day

Day One

Day Two

Explore the Agenda

7:00 am Check In & Morning Coffee

7:45 am Chair’s Opening Remarks

Envisioning the Success of mRNA Therapeutics & Vaccines Enabled by Robust Biopharma Partnerships, Licensing & Capital Investment

7:55 am Biopharma Business Development & Investors Panel: Secure the Financial Future of mRNA Technology Through Trusting Investor Partnerships

8:35 am Session Reserved for ReciBiopharm

9:05 am A Look into the RNA Deals & Companies Landscape

9:15 am Advanced Patenting Considerations for mRNA Market Players & New Entrants

9:45 am Session Reserved for Cytiva

10:15 am Morning Break & Networking

Unravelling Novel Approaches for mRNA-LNP Delivery From Genetic Circuits to Gene Editing in Pre-Clinical Models – Chair

10:45 am RNA-based Genome Engineering by Target-Primed Reverse Transcription

11:15 am Platinum® Pro Protein Barcoding: Advancing mRNA Drug Development through Multiplexed mRNA Screening with Direct Protein-Level Detection

11:45 am Preclinical Evaluation of Targeted LNPs (tLNPs) for In Vivo HSC Delivery & Editing

12:15 pm Lunch & Networking Break

Unravelling Novel Approaches for Self-Amplifying RNA Technology Discoveries to Successfully Target the Tumour – Chair

1:15 pm STX-003: Targeting IL-12 Expression to Tumors via mRNA Programmed With Genetic Circuits

1:45 pm dsRNA Control in mRNA Manufacturing：From Reduction to Detection

2:15 pm Afternoon Break & Networking

The Next Wave: Turbocharging Circular RNA Technology Development Towards Effective Vaccine & Therapeutic Applications

2:45 pm Circular RNA: Transforming a Promising Technology Into Cutting-Edge Therapeutics

3:15 pm Scarless Circular mRNA-Based CAR-T Cell Therapy Exhibits Potent Pharmacological Activity

3:45 pm CircRNA Platform & the Development of Therapeutics

4:15 pm Chair’s Closing Remarks

4:30 pm End of 5th mRNA-Based Therapeutics Summit 2025

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By